Global Markets for Vaccine Technologies

The global market for vaccine technologies should grow from $38.2 billion in 2021 to $55.1 billion by 2026 with a compound annual growth rate (CAGR) of 7.6% for the period of 2021-2026.

Report Includes

• 32 data tables and 54 additional tables
• An updated review of the global market for vaccine technologies within the biopharmaceutical industry
• Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
• Evaluation and forecast the overall vaccine technologies market size (in USD millions), and corresponding market share analysis by technology, disease indication, age and geographic region
• Identification of present and future strategies within the vaccine technology market and examination of vaccines for both humans and animals
• Highlights of market opportunities for this innovation-driven vaccine technologies market, and the major regions and countries involved in market developments and their immunization schedule
• Discussion of government regulations and policies, patent analyses and upcoming technologies, R&D activities related to the vaccine technology industry
• Emphasis on COVID-19 pandemic impact on the present and future vaccines market, major COVID-19 vaccine candidates under development, and impact of outbreak on vaccine supplies
• Profile descriptions of the leading vaccine manufacturers/suppliers, including Abbott Laboratories, Bharat Biotech International Ltd., GlaxoSmithKline Plc, Merck & Co. Inc, Sanofi Pasteur SA, and Panacea Biotec Ltd.

The global market for vaccine technologies totaled $40.1 billion in 2019. The market should grow from $42.6 billion in 2020 to $57.8 billion by 2025, at a compound annual growth rate (CAGR) of 6.3% during the 2020-2025 forecast period.

Report Includes

• 34 data tables and 54 additional tables
• Descriptive overview of the global markets for vaccine technologies and their applications
• Analyses of the global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
• Evaluation of the current market size, market estimation and forecast, pipeline analysis of new products; and discussion of opportunities, drivers and challenges affecting the overall marketplace
• Brief general outlook of the recent market developments, technological advancements, government regulations and policies, patent analyses and upcoming technologies, R&D activities related to the vaccine technology industry
• Identification of present and future strategies within the vaccine technology market and examination of vaccines for both humans and animals
• Opportunities and highlights of this innovation-driven vaccine technologies market, and the major regions and countries involved in market developments and their immunization schedule
• A separate chapter on COVID-19 pandemic impact on the present and future vaccines market, major COVID-19 vaccine candidates under development, and impact of outbreak on vaccine supplies
• Detailed company profiles of the market leading participants, including Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bayer Animal Health, GlaxoSmithKline (GSK), Merck & Co. Inc., Johnson & Johnson Inc., Novartis, Pfizer, Sanofi Pasteur and Thermo Fisher Scientific

The global market for vaccine technologies reached $35.7 billion in 2017 and should reach nearly $46.6 billion by 2022, at a compound annual growth rate (CAGR) of 5.5% for the period of 2017-2022.

Report Includes

• 92 tables
• An overview of the global market for vaccine technologies
• Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
• A review of vaccine technology and its challenges, innovations, opportunities, and regulatory hurdles
• Evaluations of market sizes and developments for vaccine classes (prophylactic and therapeutic), vaccine types (inactivated, conjugate, attenuated, recombinant vector, subunit, toxoid, combination, and dendritic cells), vaccine end users (humans and animals) and disease indications (infectious, cancer, and allergy)
• Examination of the industry environment, strategies, market influences, and driving forces
• Qualitative study of vaccine-preventable viral animal diseases found in companion animals and their necessary vaccines such as coronavirus, rotavirus and canine parvovirus etc.
• Identification of regional market sizes, prices, and trends
• Analysis of relevant patents
• Company profiles of major key players in the market, including Abbott Laboratories., Baxter International Inc., Bayer Animal Health, GE Healthcare, Glaxosmithkline Plc, Johnson & Johnson, LG Life Sciences., Novartis Pharma AG, and Thermo Fisher Scientific

The global market for vaccine technologies reached $33.3 billion in 2016 and should reach $45.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 6.3% from 2016 to 2021.

Report Includes

• An overview of the global market for human and animal (veterinary) vaccines
• Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
• A review of vaccine technology and its challenges, innovations, opportunities and regulatory hurdles
• Evaluations of market sizes and developments for vaccine classes (prophylactic and therapeutic), vaccine types (inactivated, conjugate, attenuated, recombinant vector, subunit, toxoid, combination and dendritic cells), vaccine end-users (humans and animals) and disease indications (infectious, cancer and allergy)
• Examination of industry environment, strategies, market influences and driving forces
• Identification of regional market sizes, prices and trends
• Analysis of relevant patents
• Profiles of major players in the industry

Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.

Report Includes

• An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies.
• Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
• Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines.
• A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers.
• Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.

Global sales of human and animal vaccines reached approximately $25.2 billion in 2009. The market is expected to rise at a compound annual growth rate (CAGR) of 17.9% to reach $64.2 billion by 2015.

• The global market for vaccines is expected to reach $22.4 billion by the end of 2008. It should reach $36.3 billion by 2013, a com¬pound annual growth rate (CAGR) of nearly 11%.
• Although pediatric vaccines traditionally have had the largest share of the market, adult and therapeutic vaccines will likely usurp this position in the near future.
• Patent activity has heightened to an almost frenzied level over the study period, with as many as 250 each year for 2006 and 2007.

• The total worldwide market for prophylactic and therapeutic vaccines is estimated to be $5.8 billion in 2001.
• Growing at an average annual rate (AAGR) of 11.6%, this market is expected to approach $10 billion in 2006.
• Pediatric prophylactic vaccines make up 58% of the current market, but will show the slowest growth, at an AAGR of 8.7% through 2006.
• Adult prophylactic vaccines are the second largest group with sales of nearly $2.4 billion in 2001 and are expected to rise at an AAGR of 10.1% to more than $3.8 billion in 2006.
• Therapeutic vaccines will feature growth of more than 100% on average per year through the period, but by 2006 will still make up only 10.5% of the market.